Featured
From stealth to spotlight: with $70m Series A, ‘total allergic control’ is Excellergy's goal
Backed by $70 million in Series A funding, Excellergy emerges from stealth with a mission to lead a new era in immunology - targeting the full IgE pathway to redefine how allergic diseases are treated.
Supported by
FDA approvals - September 2025
September’s FDA approvals signaled shifting rules in biopharma - faster launches, smarter formulations, and bold plays from rising innovators and the familiar giants.
From stealth to spotlight: with $70m Series A, ‘total allergic control’ is Excellergy's goal
Backed by $70 million in Series A funding, Excellergy emerges from stealth with a mission to lead a new era in immunology - targeting the full IgE pathway to redefine how allergic diseases are treated.
New CEO of Kindbody David Stern is in the business of building families
“Fifteen to twenty years ago, a woman under 35 had a 20% chance of live birth per IVF cycle. At Kindbody, today, it’s greater than 50%,” David Stern credits lab innovation and AI for rewriting fertility’s odds.
A Legend in the making: how Ying Huang is scaling CAR-T to global markets
“After just one single infusion, about a third of patients remained in remission for five years. Some physicians even called it a functional cure,” Ying Huang underlines why CARVYKTI is reshaping expectations in oncology.
From stealth to spotlight: with $70m Series A, ‘total allergic control’ is Excellergy's goal
Backed by $70 million in Series A funding, Excellergy emerges from stealth with a mission to lead a new era in immunology - targeting the full IgE pathway to redefine how allergic diseases are treated.
New CEO of Kindbody David Stern is in the business of building families
“Fifteen to twenty years ago, a woman under 35 had a 20% chance of live birth per IVF cycle. At Kindbody, today, it’s greater than 50%,” David Stern credits lab innovation and AI for rewriting fertility’s odds.
A Legend in the making: how Ying Huang is scaling CAR-T to global markets
“After just one single infusion, about a third of patients remained in remission for five years. Some physicians even called it a functional cure,” Ying Huang underlines why CARVYKTI is reshaping expectations in oncology.
Breaking the bottleneck: why Oklo’s bet on Atomic Alchemy could change cancer care
"Some companies can’t even finish clinical trials because they can’t get enough material. It all comes down to the supply chain,” Thomas Eiden underscores why secure isotope access is critical for next-generation cancer treatment.
A Bushel of Change: Digitizing the Grain Supply Chain
“Around 80 percent of payments in agriculture are still paper checks. We’re literally burning gasoline to move paper,” Jake Joraanstad calls out the analog inefficiencies undermining agriculture’s bottom line.
Engines, Excipients, and Everyday Essentials: Elizabeth Grove on Lubrizol’s Sustainability Role
"Reducing our own footprint matters greatly, but the biggest point of impact is what our products can do; how they enhance sustainability when our customers use them; or when consumers use the products that our ingredients go into.”
One Trash Can, Infinite Possibilities: The Future of Recycling According to AMP
"I can tell Starbucks the exact number of their containers that came through - down to whether they came from a resident or a commercial business,” Tim Stuart shows how AMP’s AI turns data on trash into corporate sustainability insights.
Why Every Gigafactory Needs a Recycling Plant Next Door
"Nickel stays nickel, lithium stays lithium. If you recycle down to the elemental level, you can build them back up again and again - indefinitely,” Ryan Melsert reveals why elemental recovery is the foundation for a resilient battery supply chain.
ThredUp: Scaling Second-Hand for a Sustainable Future
"Second-hand in the U.S., and globally, is projected to nearly double by 2030. The short answer is that the world needs more resale,” ThredUp's James Reinhart reveals how partnerships, tech, and trust are fueling the recommerce boom.
From Strengthening Fleets to Smart Ships: Navigating Tanker Cycles with Ardmore
"Anybody can be a shipowner if they can raise the capital. What sets you apart is the organization you build around the ships,” Gernot Ruppelt highlights why culture and execution matter as much as fleet size in today’s tanker trade.
FDA approvals - September 2025
September’s FDA approvals signaled shifting rules in biopharma - faster launches, smarter formulations, and bold plays from rising innovators and the familiar giants.
From stealth to spotlight: with $70m Series A, ‘total allergic control’ is Excellergy's goal
Backed by $70 million in Series A funding, Excellergy emerges from stealth with a mission to lead a new era in immunology - targeting the full IgE pathway to redefine how allergic diseases are treated.
New CEO of Kindbody David Stern is in the business of building families
“Fifteen to twenty years ago, a woman under 35 had a 20% chance of live birth per IVF cycle. At Kindbody, today, it’s greater than 50%,” David Stern credits lab innovation and AI for rewriting fertility’s odds.
A Legend in the making: how Ying Huang is scaling CAR-T to global markets
“After just one single infusion, about a third of patients remained in remission for five years. Some physicians even called it a functional cure,” Ying Huang underlines why CARVYKTI is reshaping expectations in oncology.
Breaking the bottleneck: why Oklo’s bet on Atomic Alchemy could change cancer care
"Some companies can’t even finish clinical trials because they can’t get enough material. It all comes down to the supply chain,” Thomas Eiden underscores why secure isotope access is critical for next-generation cancer treatment.
When is JPM Week 2026?
All the details on when the 44th annual J.P. Morgan Healthcare Conference takes place!
Onyx @ Union Square: Shankar Musunuri, Ocugen
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Onyx @ Union Square: Mike Exton, Lexicon Pharmaceuticals
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
The future of fluorescence is smaller, smarter, and more accessible
FLIM LABS is redesigning the tools of fluorescence-lifetime imaging to enable broader access across medicine, pharma, and environmental science.
Onyx Studio Sessions: Paula Brown Stafford, Allucent
Allucent is a CRO which has overseen many therapeutics through to FDA approval.
Onyx @ Union Square: Shankar Musunuri, Ocugen
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Onyx @ Union Square: Mike Exton, Lexicon Pharmaceuticals
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
Onyx Studio Sessions: Paula Brown Stafford, Allucent
Allucent is a CRO which has overseen many therapeutics through to FDA approval.